Ozmosi | Cinhyaluronate sodium Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Cinhyaluronate sodium

Pronounced as: sin-HY-a-loo-roh-nate SOH-dee-um

Alternative Names: cinhyaluronate sodium, si-614, si614, si 614
Clinical Status: Active
Latest Update: 2026-01-16
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Seikagaku
Company Location: Asia Pacific
Company Founding Year: 1947
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cinhyaluronate sodium

Countries in Clinic: United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05411367

SIDE

P3

Completed

Dry Eye Disease|Keratoconjunctivitis Sicca|Dry Eye Syndromes

2023-03-02

7%

2026-01-17

Primary Endpoints

Recent News Events

Date

Type

Title